Panel talk about Inify’s second quarter 2023
The second quarter of 2023 marked an important milestone for Inify Laboratories - the opening of the laboratory in Solna/Stockholm to offer prostate cancer diagnostic services for urology clinics and their patients.
Listen to CEO Fredrik Palm and Laboratory Manager Emelie Edvigsson in this panel talk, led by Ole Eikeland, where they explain some of the success factors for Inify's first laboratory. Some highlights include the positive customer feedback, the strategic partnerships and the importance of a tailor-made Laboratory Information System, LIS, to support the workflow instead of forcing the workflow to adapt to the system.
The lab opened in June and had customers from the start. Their patients now have a shorter waiting time to receive their prostate cancer diagnosis, which is always done with focus on image quality and by pathologists specialized in prostate cancer.
For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. The report is assisted by Inify's own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
Tags: